Table 1.
LncRNAs | Role | Expression | Target genes and/or pathways | Reference |
---|---|---|---|---|
Platinum resistance | ||||
PCAT-1 | Oncogene | Upregulated | miRNA-128/EZH2 | 54 |
UCA1 | Oncogene | Upregulated | PI3K/AKT | 56 |
DANCR | Oncogene | Upregulated | MDR1, MRP1 | 57 |
HOTAIR | Oncogene | Upregulated | miRNA-126; PI3K/AKT | 58 |
BCAR4 | Oncogene | Upregulated | Wnt/β-catenin | 59 |
HOXD-AS1 | Oncogene | Upregulated | EZH2 | 64 |
FAM84B-AS | Oncogene | Upregulated | Unknown | 65 |
TP73-AS1 | Oncogene | Upregulated | HMGB1/RAGE | 66 |
ASB16-AS1 | Oncogene | Upregulated | NF-κB | 67 |
HOTTIP | Oncogene | Upregulated | HMGA1/miRNA-218 | 69 |
MALAT1 | Oncogene | Upregulated | miRNA-30e/ATG5 | 60-63 |
PVT1 | Oncogene | Upregulated | miRNA-3619-5p/TBL1XR1 | 68 |
ADAMTS9-AS2 | Tumor suppressor | Downregulated | miRNA-223-3p/NLRP3 | 70 |
CRAL | Tumor suppressor | Downregulated | miRNA-505/CYLD | 71 |
DOX resistance | ||||
GAS5 | Tumor suppressor | Downregulated | Unknown | 72 |
HOTAIR | Oncogene | Upregulated | miRNA-17-5p | 74 |
CASC9 | Oncogene | Upregulated | MDR1 | 73 |
MRUL | Oncogene | Upregulated | ABCB1 | 75 |
UCA1 | Oncogene | Upregulated | PARP1, Bcl-2, miRNA-27b | 76, 134 |
D63785 | Oncogene | Upregulated | miRNA-422a | 78 |
NEAT1 | Oncogene | Upregulated | Unknown | 79 |
ROR | Oncogene | Upregulated | MRP1 | 81 |
5-FU resistance | ||||
FAM83H-AS1 | Oncogene | Upregulated | miRNA-145-5p | 82 |
MACC1-AS1 | Oncogene | Upregulated | MDR1, MRP1 | 83 |
ANRIL | Oncogene | Upregulated | PI3K/AKT/mTOR | 84 |
XLOC_006753 | Oncogene | Upregulated | miRNA-153-5p/CITED2 | 85 |
FGD5-AS1 | Oncogene | Upregulated | Unknown | 86 |
LEIGC | Tumor suppressor | Downregulated | miRNA-145-5p | 87 |
Paclitaxel resistance | ||||
ZFAS1 | Oncogene | Upregulated | Wnt/β-catenin | 89 |
MALAT1 | Oncogene | Upregulated | miRNA-23b-3p | 90 |
PVT1 | Oncogene | Upregulated | MDR1, MRP, mTOR and HIF-1α | 91 |
HOTAIR | Oncogene | Upregulated | miRNA-217 | 92 |
CASC9 | Oncogene | Upregulated | MDR1 | 73 |